Glaukos Plunges 11.2% After BTIG Maintains Buy
Glaukos Corporation shares dropped 11.2% despite BTIG maintaining a "Buy" rating and raising its price target from $141 to $162. This disconnect suggests investor concerns outweigh analyst optimism, possibly due to skepticism about underlying assumptions or unaddressed near-term headwinds in the medical devices sector. Investors are urged to monitor management's commentary on sales trends or competitive dynamics to understand the market's reaction.
GKOS Maintained by BTIG -- Price Target Raised to $162
BTIG analyst Ryan Zimmerman maintained a 'Buy' rating on Glaukos (GKOS) and raised its price target from $141.00 to $162.00, indicating increased confidence in the company. Despite this positive sentiment, GuruFocus assesses GKOS as approximately 8.1% overvalued, with insiders selling $6.5 million in stock over the past three months. While the company shows strong growth and momentum with a GF Score™ of 81/100, its profitability remains an area for improvement.
BTIG raises Glaukos stock price target to $162 on product pipeline
BTIG has raised its price target for Glaukos Corporation (NYSE: GKOS) to $162, maintaining a Buy rating, citing the company's strong product pipeline, including iDose and Epioxa. This adjustment follows Glaukos' impressive first-quarter 2026 results, which saw a 41% year-over-year revenue increase. Despite the positive outlook from analysts and strong performance, InvestingPro analysis suggests the stock might be overvalued, and profitability is not anticipated this year.
Glaukos director Kliman sells $703,800 in stock
Glaukos director Gilbert H. Kliman sold 5,000 shares of company stock for $703,800 after exercising stock options. The sale occurred while the stock was near its 52-week high, and the company has shown strong financial performance, exceeding Q1 2026 earnings and revenue forecasts, leading to raised revenue guidance and positive analyst reactions.
Glaukos director Kliman sells $703,800 in stock By Investing.com
Glaukos director Gilbert H. Kliman sold 5,000 shares of the company's common stock for $703,800 after acquiring them through stock options. This transaction occurred while the stock was near its 52-week high and is considered overvalued according to InvestingPro analysis. The medical device company recently reported strong first-quarter 2026 earnings, exceeding forecasts and prompting analysts to raise price targets.
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest
Glaukos Corp (GKOS) shares recently hit new 52-week highs, drawing investor attention. This comes as a company director sold a significant number of shares after exercising options, while institutional ownership remains high. The company specializes in ophthalmic devices for chronic eye diseases and is investing heavily in R&D, leading to current negative earnings despite strong revenue growth and market interest.
Glaukos stock hits 52-week high at $146.90 By Investing.com
Glaukos (GKOS) stock has reached a new 52-week high of $146.75, with shares trading at $147.14, representing a 50.84% total return over the past year. This milestone follows a 36.3% revenue growth and Q1 2026 results that surpassed analyst expectations, leading to raised revenue guidance and increased price targets from several analyst firms. Despite these positive indicators, InvestingPro Tips suggest the stock is currently in overbought territory, and analysts do not anticipate profitability this year.
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares
A director at Glaukos (NYSE: GKOS), Gilbert H. Kliman, recently exercised stock options for 5,000 shares at $24.69 per share and subsequently sold all 5,000 shares in the open market for an average price of $140.76 per share. Following these transactions, Kliman directly holds 35,528 shares of common stock, which includes certain restricted stock units. This activity is a common practice for insiders managing their equity compensation.
Glaukos director Kliman sells $703,800 in stock
Glaukos Corp. director Gilbert H. Kliman sold 5,000 shares of company stock for $703,800 on May 14, 2026, after exercising options to acquire the same number of shares. The sale occurred while the stock was near its 52-week high, and Kliman now directly holds 35,528 shares. This transaction follows Glaukos' strong first-quarter 2026 earnings, which surpassed revenue and EPS forecasts, leading analysts to raise price targets.
Glaukos stock hits 52-week high at $146.90 By Investing.com
Glaukos (GKOS) stock has reached a new 52-week high of $146.75, with shares trading at $147.14, representing a significant 50.84% total return over the past year. This milestone, driven by 36.3% revenue growth and strong analyst consensus for a Buy rating, underscores the company's growth trajectory despite analysts not anticipating profitability this year. The company recently reported strong first-quarter 2026 results, surpassing expectations with $150.6 million in revenue and leading to increased price targets from analysts.
Glaukos (GKOS) price target increased by 12.59% to 154.96
The article reports that the price target for Glaukos (GKOS) has been increased by 12.59% to 154.96. No additional details are provided in the snippet.
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS
DNB Asset Management AS increased its stake in Glaukos Corporation (NYSE:GKOS) by 11.9% in Q4, bringing its total holdings to 82,320 shares valued at approximately $9.3 million. Other institutional investors also raised their positions, with 99.04% of the stock now held by hedge funds and institutions. Despite recent insider selling, analysts maintain a "Moderate Buy" rating with an average target price of $144.42, following Glaukos's beat on quarterly earnings and revenue estimates.
Glaukos Corp stock (US3773221029): eye-care specialist gains attention after FDA approval and strong Q1 momentum
Glaukos Corp, an ophthalmic pharmaceutical and medical technology developer, has attracted investor attention following FDA approval for its iDose TR implant for glaucoma and strong revenue growth in Q1 2025. The company specializes in eye-care solutions for chronic diseases like glaucoma and corneal disorders, aiming to reduce vision loss with devices and drug-eluting solutions. This article highlights Glaukos's business model, key revenue drivers, competitive position, and why it's relevant for US investors, emphasizing its transition from a niche device developer to a broader ophthalmology company.
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding
Janus Henderson Group plc has reported a beneficial ownership of 5,348,395 shares of Glaukos Corp (GKOS) common stock, representing 9.2% of the class, through an amended SCHEDULE 13G/A filing. The shares are held by multiple Janus Henderson asset managers on behalf of managed portfolios, with shared voting and dispositive power. The filing clarifies that the asset managers disclaim rights to dividend or sale proceeds from these shares.
Glaukos (NYSE:GKOS) Stock Forecast & Analyst Predictions
Glaukos (NYSE:GKOS) is forecast to significantly grow earnings and revenue, with analysts projecting gains of 70.8% and 19.2% per annum respectively. Despite a past of unprofitability, the company's price target has been increased due to strong Q1 2026 results and the momentum of new products iDose TR and Epioxa. Insider transactions show a trend of more sales than purchases, yet the company continues to update sales guidance reflecting confidence in its product pipeline and market penetration.
Glaukos Insider Sold Shares Worth $675,000, According to a Recent SEC Filing
An insider at Glaukos recently sold shares valued at $675,000, as disclosed in an SEC filing. This transaction, occurring 6 hours ago, indicates a significant sale by a company affiliate. The details of the filing would provide further context regarding the insider's identity and the quantity of shares sold.
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares
Gilbert H. Kliman, a director at Glaukos Corp (GKOS), filed a Form 144 to sell 5,000 shares of common stock, stemming from an option granted on June 2, 2016. The filing also disclosed a prior sale of 5,000 shares on May 11, 2026, which generated proceeds of $675,000. These transactions indicate insider selling activity for Glaukos Corp.
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
The article suggests that medical device stocks, after a period of underperformance, are beginning to stabilize and show signs of a bounce. Investors are rotating back into defensive growth areas within the healthcare sector. Smith & Nephew is highlighted as one company to watch, having seen a 7% increase over the last year.
Glaukos director Gilbert H Kliman sells $675,000 of company stock
Glaukos director Gilbert H Kliman sold 5,000 shares of company stock for $675,000, disposing of shares at $135.00 each on May 11, 2026. This transaction was part of an exercise-and-sell event where Kliman also acquired 5,000 shares by exercising stock options at $24.69 per share. Following these sales, Kliman directly holds 35,528 shares in GLAUKOS Corp.
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares
Gilbert H. Kliman, a director at Glaukos (NYSE: GKOS), engaged in an exercise-and-sell transaction. He acquired 5,000 shares of common stock by exercising options at $24.69 per share and simultaneously sold these 5,000 shares in the open market for $135.00 each. Following these transactions, Kliman directly holds 35,528 common stock shares, which include unvested or deferred restricted stock units.
Precision Trading with Glaukos Corporation (GKOS) Risk Zones
This article provides a detailed analysis of Glaukos Corporation (GKOS) using AI-generated signals and risk zones. It outlines near-term neutral sentiment while highlighting mid and long-term strength, along with specific position trading, momentum breakout, and risk hedging strategies. The analysis includes support and resistance levels across different timeframes for precision trading.
Glaukos Corp stock (US3773221029): Insider files Form 144 for 5,000-share sale
An insider at Glaukos Corp (NYSE: GKOS) filed a Form 144 notice to sell 5,000 common shares valued at $675,000 on May 11, 2026. This transaction aligns with standard insider reporting and occurs as the ophthalmic medical technology firm prepares for upcoming investor conferences. Glaukos specializes in therapies for glaucoma and retinal diseases, with its iStent inject system being a key product driver in the US market.
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation has announced its participation in four upcoming investor conferences in May and June 2026, including the Stifel Virtual Ophthalmology Forum, William Blair 46th Annual Growth Stock Conference, Jefferies Global Healthcare Conference, and Truist MedTech Conference. Webcasts for applicable events will be available on the company's investor relations website. The company specializes in ophthalmic pharmaceutical and medical technology for treating glaucoma, corneal disorders, and retinal diseases.
Glaukos Corporation to Participate in Upcoming Investor Conferences
Glaukos Corporation, a company specializing in ophthalmic medical technology and pharmaceutical products, announced its participation in several upcoming investor conferences. These events will allow Glaukos to connect with investors, providing a platform to discuss their business strategies and financial performance. The company aims to engage effectively with the investment community.
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation has announced its management will participate in four upcoming investor conferences in May and June 2026, including the Stifel Virtual Ophthalmology Forum, William Blair 46th Annual Growth Stock Conference, Jefferies Global Healthcare Conference, and Truist MedTech Conference. Webcasts of these events will be available on the Investors section of the Glaukos website. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on treatments for glaucoma, corneal disorders, and retinal diseases.
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE: GKOS) announced its management will participate in four upcoming investor conferences in May and June 2026. These events include the Stifel Virtual Ophthalmology Forum, William Blair 46th Annual Growth Stock Conference, Jefferies Global Healthcare Conference, and Truist MedTech Conference. Webcasts of these presentations will be available on the Glaukos investor relations website.
[144] GLAUKOS Corp SEC Filing
This article reports on Glaukos Corp's (GKOS) recent SEC filing, Form 144, indicating a proposed sale of 5,000 shares of common stock with an aggregate market value of $675,000. The securities were acquired via an option grant on May 11, 2026, from the Issuer and are intended to be sold on the NYSE. The filing notes Fidelity Brokerage Services LLC as the broker for the sale.
Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile
Glaukos Corp has increased its 2026 net sales guidance to $620 million to $635 million, reflecting strong demand for its interventional glaucoma and keratoconus therapies. Despite this positive outlook and rapid revenue growth, the stock trades below some fair-value estimates, possibly due to a discount for execution risk or its still-negative net income. The company is strategically expanding its product offerings and global presence in ophthalmic medical technology.
Glaukos (GKOS) Is Up 15.7% After Raising 2026 Sales Guidance And Expanding Ophthalmic Portfolio – What's Changed
Glaukos (GKOS) saw a 15.7% increase after raising its 2026 net sales guidance to US$620 million to US$635 million, following Q1 2026 sales of US$150.57 million. The company is expanding its ophthalmic portfolio, with key commercialization efforts focused on iDose and Epioxa, the latter securing a permanent J code effective July 1, 2026, which is expected to ease reimbursement. Despite continued net losses and high investment needs, the raised guidance and progress with key products reinforce Glaukos's long-term growth plan, though challenges remain in product uptake and reimbursement.
Glaukos (GKOS) Is Up 15.7% After Raising 2026 Sales Guidance And Expanding Ophthalmic Portfolio – What's Changed
Glaukos (GKOS) saw a 15.7% stock increase after raising its 2026 net sales guidance to $620 million to $635 million and expanding its ophthalmic portfolio, following strong Q1 2026 sales of $150.57 million. The company's investment narrative is bolstered by the potential for successful commercialization of iDose and Epioxa, especially with Epioxa gaining a permanent J code for reimbursement. However, continued net losses and high investment needs pose ongoing risks.
Glaukos outlines $620M-$635M 2026 net sales outlook following Q1 outperformance
Glaukos (NYSE:GKOS) provided a net sales outlook of $620 million to $635 million for 2026, driven by an impressive first-quarter performance where the ophthalmic medical technology and pharmaceutical company exceeded revenue expectations. The company also announced a new $100 million share repurchase program and updated its full-year 2024 net sales guidance to $330 million-$335 million, up from $325 million-$330 million. This positive outlook follows strong performance across its glaucoma, corneal health, and dry eye portfolios.
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares
Glaukos SVP & CFO Alex Thurman sold 10,000 shares of Glaukos Corp (NASDAQ:GKOS) for $1.4 million on April 30, 2026, after exercising options for an equal number of shares. The sale price of $140.00 per share is near the stock's 52-week high, and the transaction was executed under a Rule 10b5-1 trading plan. This comes as Glaukos reported strong Q1 2026 results, beating analyst expectations and raising its full-year revenue guidance.
GLAUKOS (GKOS) director Leana Wen sells 1,700 shares, holds 19,739
GLAUKOS Corp director Leana Wen has reported an open-market sale of 1,700 shares of common stock at $143.35 per share. Following this transaction, Wen directly holds 19,739 shares, which includes 2,731 restricted stock units that are either unvested or have deferred delivery. The sale amounted to $243,695 and was detailed in a Form 4 SEC filing.
Glaukos president & COO Gilliam sells $2.8m in company stock
Joseph E. Gilliam, President & COO of Glaukos Corp, sold 19,573 shares of common stock for over $2.8 million at $143.54 per share. This transaction occurred amidst the stock being deemed overvalued by InvestingPro analysis, despite recent strong Q1 2026 financial results that saw Glaukos' revenue grow by 41% year-over-year. Following the sale, Gilliam retains 73,419 shares, including restricted stock units.
GLAUKOS (GKOS) President & COO sells 19,573 shares in open-market trade
Joseph E. Gilliam, President and COO of GLAUKOS Corp (GKOS), reported an open-market sale of 19,573 shares of common stock at a price of $143.54 per share. Following this transaction, Gilliam directly holds 73,419 shares, which includes 43,925 restricted stock units that are not yet vested. The sale, valued at approximately $2.81 million, was disclosed in a Form 4 insider filing.
Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148
Glaukos Corporation recently reported strong first-quarter results, with revenues exceeding analyst forecasts. Following these results, analysts have updated their financial projections for 2026, slightly increasing revenue forecasts but also raising loss per share estimates. Despite intensifying losses, the consensus price target for Glaukos has been lifted to US$148, driven by expectations of significant revenue growth that outpaces the broader industry.
Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148
Glaukos Corporation (NYSE:GKOS) recently reported strong first-quarter results, with revenues surpassing analyst forecasts and statutory losses being smaller than expected. Following these results, analysts have raised their revenue forecasts for 2026 to US$630.8 million and increased the consensus price target by 6.2% to US$148, despite anticipating higher losses per share. The company is expected to significantly outpace the industry in revenue growth, with an annualized growth forecast of 20% to the end of 2026.
Glaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Glaukos (NYSE:GKOS) from a "hold" to a "buy" rating, reflecting a broader positive sentiment from analysts following strong Q1 results. Glaukos beat revenue and EPS estimates, leading to a raised 2026 revenue outlook and multiple price target increases. Despite insider selling, institutional ownership is high, and the company maintains a "Moderate Buy" consensus rating with an average target price of $138.85.
Glaukos Corp. Earnings Call Signals Growth Momentum
Glaukos Corp. reported record first-quarter revenue growth of 41% year-over-year, reaching $150.6 million, largely driven by its U.S. glaucoma franchise and the iDose TR implant. The company raised its 2026 net sales guidance to $620 million to $635 million, demonstrating strong momentum and a deep pipeline despite some near-term challenges with its new corneal therapy, Epioxa. While Epioxa's initial uptake faces payer adoption and reimbursement hurdles, Glaukos is addressing these and projects continued growth, balancing investment with a path towards cash-flow breakeven.
[144] GLAUKOS Corp SEC Filing
This article reports on a Form 144 SEC filing by Glaukos Corp (GKOS). The filing indicates a proposed sale of 1700 shares of common stock with an aggregate market value of $247,095.17, acquired through restricted stock vesting as compensation. Fidelity Brokerage Services LLC is listed as the broker for the sale, which is scheduled for May 1, 2026.
Glaukos (GKOS) Jumps As Earnings Beat Fuels Bullish Outlook
Glaukos (GKOS) stock surged over 22% after reporting Q1 earnings and revenue that beat expectations, driven by strong demand for its iDose TR and Epioxa products. The company also provided an optimistic 2026 revenue guidance above Street estimates and secured a crucial permanent CMS J-code for Epioxa, which is expected to streamline reimbursement and expand market access. Citi reaffirmed its Buy rating and raised its price target for GKOS, highlighting it as a strong performer in the med-tech sector.
Glaukos (GKOS) Rule 144: Fidelity lists 10,000‑share resale, insider trades
Glaukos Corp. has filed a Rule 144 notice for the proposed resale of 10,000 shares of common stock by Fidelity Brokerage Services LLC. The filing also details recent open-market dispositions by Alex R. Thurman, totaling 4,657 shares across March 17, 24, and 25, 2026, with reported cash proceeds for each transaction. This regulatory notice indicates that previously restricted shares are becoming available for public sale, which could impact the company's liquidity and stock price.
Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript
Glaukos Corporation reported record first-quarter net sales of $150.6 million, up 41% year-over-year, leading them to raise their full-year 2026 net sales guidance. The growth was primarily driven by strong performance in their U.S. glaucoma franchise, particularly with iDose TR, and the initial commercial launch of Epioxa for keratoconus. The company emphasized its continued investment in a robust pipeline and disciplined capital allocation to achieve operating leverage and cash flow breakeven.
BTIG raises Glaukos stock price target to $141 on strong results
BTIG has raised its price target for Glaukos Corporation (NYSE:GKOS) to $141 from $131, maintaining a Buy rating after the company reported strong first-quarter 2026 results. Glaukos exceeded revenue estimates with $150.6 million, an increase of 41% year-over-year, and raised its full-year 2026 revenue guidance. Despite strong gross profit margins and revenue growth, InvestingPro notes the company remains unprofitable over the last twelve months.
Glaukos Announces 41 Percent First Quarter Sales Increase Fueled by Two Treatments
Glaukos Corporation reported a 41 percent increase in first-quarter net sales, reaching $150.6 million, largely driven by its glaucoma treatments which saw a 47 percent year-over-year growth. The company attributes this success to the strong performance of iDose TR and the recent commercial availability of Epioxa for keratoconus. Glaukos also reaffirmed its full-year 2026 net sales guidance, projecting $620 million to $635 million.
Glaukos Announces First Quarter 2026 Financial Results
Glaukos Corporation announced strong first-quarter 2026 financial results, with record net sales of $150.6 million, an increase of 41% year-over-year. The company raised its 2026 net sales guidance to a range of $620 million to $635 million, citing successful global execution and promising growth drivers like iDose TR and Epioxa. Despite an operating loss of $19.9 million, Glaukos highlighted its robust pipeline and ending the quarter with $280.5 million in cash and no debt.
Universal Beteiligungs und Servicegesellschaft mbH Purchases 11,821 Shares of Glaukos Corporation $GKOS
Universal Beteiligungs und Servicegesellschaft mbH has increased its stake in Glaukos Corporation by 37.9%, purchasing an additional 11,821 shares to own a total of 42,996 shares valued at approximately $4.86 million, representing about 0.07% of the company. This institutional buying contrasts with recent insider selling, which saw Glaukos executives sell 19,657 shares worth around $2.25 million. Glaukos reported Q4 revenue of $143.12 million, exceeding estimates, but missed on EPS with ($0.28).
Earnings call transcript: Glaukos Corp beats Q1 2026 forecasts, stock dips
Glaukos Corp (GKOS) reported strong Q1 2026 results, exceeding revenue and EPS forecasts with significant year-over-year growth, driven by its Glaucoma and Corneal Health franchises. Despite the positive financial performance and raised full-year revenue guidance, the stock experienced a slight dip in after-hours trading. The company is confident in its strategic focus on product innovation, market expansion, and addressing challenges like rising operating expenses and competitive pressures.
Glaukos Boosts Outlook After Strong First-Quarter 2026 Results
Glaukos (GKOS) reported strong first-quarter 2026 results, with record net sales of $150.6 million, a 41% year-over-year increase, driven by significant growth in glaucoma revenue. The company raised its full-year 2026 net sales guidance to $620 million–$635 million, citing robust global execution and strong uptake of products like iDose TR and Epioxa. Despite remaining modestly loss-making, Glaukos maintains a strong financial position with $280.5 million in cash and no debt, while also enhancing investor transparency.
Earnings Flash (GKOS) Glaukos Corporation Reports Q1 Revenue $150.6M, vs. FactSet Est of $137.0M
Glaukos Corporation (GKOS) reported strong Q1 revenue of $150.6 million, significantly exceeding FactSet estimates of $137.0 million. The company also narrowed its Q1 non-GAAP loss and raised its 2026 sales outlook, now expecting revenue in the range of $620M-$635M, surpassing the previous FactSet estimate. This positive financial performance was accompanied by recent product launches and approvals for Epioxa, a treatment for keratoconus.
